A combined oral contraceptive (COC) containing 15 mg E4 and 3 mg DRSP administered for 24
days followed by 4 placebo tablets, is being evaluated for further development. This study
will investigate the effect of this COC on ovarian function inhibition, levels of serum
luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol (E2) and progesterone
during 3 treatment cycles in comparison with the reference COC 20 mcg EE/3 mg DRSP.